NASDAQ: VCRE
Vicore Pharma Holding Ab Stock

$9.41-0.50 (-5.05%)
Updated Nov 20, 2026
VCRE Price
$9.41
Fair Value Price
$2.38
Market Cap
N/A
52 Week Low
$7.88
52 Week High
$17.80
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
N/A
Beta
0.54
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

VCRE Overview

Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine VCRE's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
VCRE
Ranked
#122 of 447

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important VCRE news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VCRE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VCRE ($9.41) is overvalued by 295.16% relative to our estimate of its Fair Value price of $2.38 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VCRE ($9.41) is not significantly undervalued (295.16%) relative to our estimate of its Fair Value price of $2.38 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VCRE's short-term assets ($113.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more VCRE due diligence checks available for Premium users.

Valuation

VCRE fair value

Fair Value of VCRE stock based on Discounted Cash Flow (DCF)

Price
$9.41
Fair Value
$2.38
Overvalued by
295.16%
VCRE ($9.41) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VCRE ($9.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

VCRE's financial health

Profit margin

Revenue
$64.4k
Net Income
-$11.6M
Profit Margin
-18,042.5%

Assets to liabilities

Assets
$115.2M
Liabilities
$9.2M
Debt to equity
0.09
VCRE's short-term assets ($113.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VCRE's short-term assets ($113.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VCRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$12.6M
Investing
-$9.5M
Financing
$0.0

VCRE vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ABUSC$616.24M-1.23%3.53x7.19x
ABVC–$23.36M-1.59%-5.41x1.79x
AARDF$20.21M-7.70%-0.28x0.35x
ADAGC$118.17M-12.44%-4.69x1.32x
ONCA$44.70B-2.19%630.55x7.68x

Vicore Pharma Holding Ab Stock FAQ

What is Vicore Pharma Holding Ab's quote symbol?

(NASDAQ: VCRE) Vicore Pharma Holding Ab trades on the NASDAQ under the ticker symbol VCRE. Vicore Pharma Holding Ab stock quotes can also be displayed as NASDAQ: VCRE.

If you're new to stock investing, here's how to buy Vicore Pharma Holding Ab stock.

What is the 52 week high and low for Vicore Pharma Holding Ab (NASDAQ: VCRE)?

(NASDAQ: VCRE) Vicore Pharma Holding Ab's 52-week high was $17.80, and its 52-week low was $7.88. It is currently -47.13% from its 52-week high and 19.42% from its 52-week low.

How much is Vicore Pharma Holding Ab's stock price per share?

(NASDAQ: VCRE) Vicore Pharma Holding Ab stock price per share is $9.41 today (as of Nov 20, 2026).
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.